Please use this identifier to cite or link to this item:
Title: Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells
Author: Fernández Rodríguez, Concepción
Salar, Antonio
Navarro Ponz, Alfons
Gimeno Vázquez, Eva
Pairet, Silvia
Camacho, Laura
Ferraro, Mariana
Serrano, Sergi
Besses, Carles
Bellosillo, Beatriz
Sánchez González, Blanca
Keywords: Tumors
Cèl·lules B
B cells
Issue Date: 3-Mar-2016
Publisher: Harwood Academic Publishers
Abstract: Current standard-of-care therapy for diffuse large B-cell lymphoma (DLBCL) results in up to 40% of patients who either relapse or develop refractory disease. In this setting, further therapeutic improvements are needed. This study analyzed the in vitro effects of the combination of bendamustine with the histone deacetylase inhibitor vorinostat in DLBCL cells. This combination enhanced histone acetylation and double strand DNA breaks resulting in an additive to synergistic cytotoxic effect in both ABC- and GCB-type DLBCL cells, independently of their TP53 mutational status. These results support the rationale for considering bendamustine and vorinostat combination as a novel approach in DLBCL treatment.
Note: Versió postprint del document publicat a:
It is part of: Leukemia & Lymphoma, 2016, vol. 57, num. 3, p. 692-699
Related resource:
ISSN: 1042-8194
Appears in Collections:Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)

Files in This Item:
File Description SizeFormat 
666352.pdf682.26 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.